



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: June 29, 2020

To
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Reg: Security Code No. 530233:

Sub: Outcome of the Board Meeting dated June 29, 2020:

Dear Sir / Ma'am,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. **Monday, June 29, 2020**), has Approved the Audited Standalone Financial Results of the Company for the quarter & year ended on March 31, 2020 as recommended by the Audit Committee.

In this regard, we are enclosing herewith:

- Audited Standalone Financial Results for the quarter & year ended March 31, 2020 along with the Statement of Assets and Liabilities of the Company and Cash-Flow Statement as on that date.
- Auditors Report on the Financial Results for the quarter & year ended March 31, 2020.
- Declaration regarding Auditor's Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the financial year ended on March 31, 2020.

The Meeting of the Board commenced at 2.00 p.m. and concluded at 3.20 p.m. The results will be published in the newspaper pursuant to Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully,
For AURO LABORATORIES LIMITED

S. J. Deorah

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796



Encl.: as above


AURO LABORATORIES LIMITED
CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR
BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

PART - I		(Rs. In Lakhs except EPS)				
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2020						
Sr. No.	Particulars	3 Months ended	3 Months ended	Corresponding 3 Months ended in the Previous Year	For the Year Ended	Previous Year Ended
		31.03.2020 <i>(Audited)</i>	31.12.2019 <i>(Unaudited)</i>	31.03.2019 <i>(Audited)</i>	31.03.2020 <i>(Audited)</i>	31.03.2019 <i>(Audited)</i>
1	Income from Operations					
	(a) Net Sales/Income from Operations (Net of excise duty)	942.83	954.40	1153.015	4,379.06	4,682.31
2	Other Income	38.19	10.76	59.34	97.26	95.82
3	Total Revenue (1 + 2)	981.02	965.16	1,212.36	4,476.32	4,778.13
4	Expenses					
	a. Consumption of raw material	367.69	350.35	621.14	2,342.21	3,013.82
	b. Purchase of Stock-in-trade	30.86	-	23.87	56.61	24.91
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	119.97	95.32	(8.65)	49.18	(176.59)
	d. Employee benefits expense	184.91	136.68	132.32	527.54	407.07
	e. Finance Cost	9.84	9.82	12.57	46.63	72.22
	f. Depreciation and amortisation expenses	23.33	28.00	22.42	102.33	100.92
	g. Other Expenses	167.68	213.6	177.535	787.64	728.89
	Total Expenses (4)	904.29	833.77	981.21	3,912.14	4,171.24
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	76.73	131.39	231.15	564.18	606.89
6	Exceptional items	-	-	-	-	-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	76.73	131.39	231.15	564.18	606.89
8	Extraordinary items	-	-	-	-	-
9	Profit / (Loss) before tax (7 ± 8)	76.73	131.39	231.15	564.18	606.89
10	Tax expense*	-	-	-	-	-
	(a) Current tax expenses for current year	24.12	27.55	67.76	152.48	161.69
	(b) MAT credit (where applicable)	-	-	-	-	-
	(c) Defferered tax	6.25	-	5.25	6.25	5.25
11	Profit / (Loss) for the period from continuing operation (9± 10)	46.36	103.84	158.15	405.45	439.95
12	Profit / (Loss) for discontinuing operations	-	-	-	-	-
13	Tax expense of discontinuing operations	-	-	-	-	-
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	46.36	103.84	158.15	405.45	439.95
15	Other Comprehensive Income	11.22	25.16	8.11	11.22	8.11
16	Total Comprehensive Income for the period (14 ± 15)	57.58	129.00	166.26	416.67	448.06
17	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	1,526.51	1,117.95
19	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):					
	(a) Basic	0.74	1.67	2.54	6.51	7.06
	(b) Diluted	0.74	1.67	2.54	6.51	7.06



Notes:

- 1) The above audited financial results for the quarter and year ended 31st March, 2020 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 29th June, 2020.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) The above audited results, published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been prepared in accordance with Indian Accounting Standards (IND AS) notified under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015; Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and guidelines issued by the Securities and Exchange Board of India (SEBI) and other accounting principles generally accepted in India.
- 4) Figures of last Quarter are the balanceing figures between audited figures in respect of the full financial year and the publised year to the date upto the third quarter of the current financial year.
- 5) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

Siddhartha Deorah



**SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN NO. 00230796**

**Place : Mumbai
Date : 29.06.2020**

Auro Laboratories Limited

Statement of Assets and Laibilities (Ind AS)

(Rs. In Lakh)

Particulars	As at 31.03.2020	As at 31.03.2019
	Audited	Audited
A ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	1,423.52	1,458.62
(b) Capital Work -in-Progress	11.60	11.60
(c) Investment Property	-	-
(d) Financial Assets		
(i) Investments	4.88	4.88
(ii) Loans	-	-
(iii) Others	-	-
(e) Other non-current assets - Capital Advance	-	-
2. Current assets		
(c) Inventories	406.25	337.38
(b) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade Reveivables	577.98	850.38
(iii) Cash and cash equivalentls	503.46	335.88
(iv) Bank balances other than (iii) above	64.96	74.88
(v) Loans	-	-
(vi) Others	242.17	272.92
(c) Other Current Assets	-	-
TOTAL ASSETS	3234.82	3346.54
B EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	623.25	623.25
(b) Other Equity	1,526.51	1,117.95
2. Liabilities		
(I) Non-Current Liabilities		
(a) Financial Liabilities	180.98	614.93
(i) Other Financial Liabilities	134.62	194.50
(b) Provisions	-	-
(c) Deferred Tax Liabilities (Net)	155.91	149.67
(d) Other Non-Current Liabilities	-	-
(II) Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	473.83	518.32
(b) Other Current Liabilities	69.47	78.10
(c) Provisions	70.25	49.82
(d) Current Tax Liabilities (net)	-	-
TOTAL EQUITY AND LIABILITIES	3234.82	3346.54



Cash Flow Statement

Particulars	For the year ended 31.03.2020		For the year ended 31.03.2019	
	Amount	Amount	Amount	Amount
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		564.18		606.89
Add: Adjustments for:				
Depreciation and amortisation	102.33		100.92	
Other Non Cash Items	11.22		8.11	
Finance costs	46.63	160.18	72.22	181.25
		724.36		788.14
Less: Adjustment for:				
Interest income	7.01		9.10	
Dividend income	0.06	7.07	0.03	9.13
Operating profit / (loss) before working capital changes		717.29		779.01
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	(68.87)		(188.28)	
Trade receivables	272.40		(12.89)	
Loans and advances	30.75		141.32	
Other Bank Balance			-	
Other non-current assets		234.28	-	(59.85)
		951.57		719.16
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	(44.49)		(11.79)	
Other current liabilities	(8.63)		4.82	
Other long-term liabilities				
Short-term provisions	20.43		(25.11)	
Long-term provisions				
		(32.69)		(32.08)
		918.88		687.08
Cash flow from extraordinary items				-
Cash generated from operations		918.88		687.08
Net income tax (paid) / refunds		-		-
Net cash flow from / (used in) operating activities (A)		918.88		687.08
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advance	(67.23)		(161.52)	
Proceeds from sale of fixed assets				
Interest received				
- Others	7.01		9.10	
Dividend received				
- Others	0.06		0.03	
		(60.16)		(152.39)



Net income tax (paid) / refunds		(160.60)		(166.32)
Net cash flow from / (used in) investing activities (B)		(220.76)		(318.71)
C. Cash flow from financing activities				
Proceeds from long-term borrowings				
Repayment of borrowings & Net increase / (decrease) in working capital borrowings	(80.76)		(2.91)	
Proceeds from other short-term borrowings	(353.19)			
Repayment of other short-term borrowings	(59.88)		(107.50)	
Finance cost	(46.63)		(72.22)	
		(540.46)		(182.63)
Cash flow from extraordinary items				-
Net cash flow from / (used in) financing activities (C)		(540.46)		(182.63)
Net increase/(decrease) in Cash & cash equivalents (A+B+C)		157.66		185.74
Cash and cash equivalents at the beginning of the year		410.75		225.01
Cash and cash equivalents at the end of the year		568.41		410.75

FOR & BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED

Siddhartha Deorah
SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN NO. 00230796



Place : Mumbai
Date : 29.06.2020




KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS

To,
The Board of Directors,
Auro Laboratories Limited.

1. We have audited the accompanying Statement of Standalone Financial Results of Auro Laboratories Ltd. ("the company") for the quarter and year ended March 31, 2020, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.
2. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement as it relates to the quarter ended March 31, 2020, has been compiled from the related interim condensed standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2020, had been compiled from the related annual standalone financial statements prepared under Section 133 of the Companies Act, 2013 read with rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim condensed standalone financial statements and annual standalone financial statements.

Further, we report that the figures for the quarter ended March 31, 2020 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2020 and the published year to date figures up to December 31, 2019 being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated above as required under the Listing Regulations and circular.

3. We conducted our audit in accordance with the Standards on Auditing issued by Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement(s).





KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS


An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statements.

We believe that the evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
- (i) is presented in accordance with requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, and
 - (ii) gives a true and fair view, in conformity with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the profit, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2020.

For Khurdia Jain & Co.
Chartered Accountants
(Firm Reg. No. 120262)


Sampat Khurdia
Partner



Membership No. 033615
UDIN : 20033615AAAAAV4339
Place: Mumbai
Date: 29/06/2020



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: June 29, 2020.

To
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Reg: Security Code No. 530233

Sub: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Ma'am,

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI / LAD-NRO / GN / 2016-17 / 001 dated May 25, 2016 read with SEBI Circular No. CIR / CFD / CMD / 56 / 2016 dated May 27, 2016, We hereby declared that the Statutory Auditors of the Company M/s. Khurdi Jain & Co, Chartered Accountants, Mumbai (Firm Registration No. 120263W) have issued the Audit Reports with Unmodified Opinion in respect of the Audited Standalone Financial results for the quarter & year ended on March 31, 2020.

Kindly take the same on your record.

Thanking you,

For AURO LABORATORIES LIMITED

Siddhartha Deorah

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796

